

FIELD DATES: 16APR07 to 23MAY07

MM = Menopause Management focus, based on self-identification from answer to Q6A

General = Menopause Management not a focus, based on answer to Q6A

Data are weighted by medical specialty and menopause management focus. Percentages shown are weighted; n's are unweighted.

1. What is your primary medical specialty?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Family or General Practitioner	29%	23%	40%
Internal Medicine	27	18	42
Obstetrician/Gynecologist	40	56	13
Endocrinologist	4	3	5
Other specialty (TERMINATE)	-	-	-

2. Approximately what percent of your working day is devoted to clinical practice?
 TERMINATE IF LESS THAN 70%

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
70%-89%	4%	4%	5%
90%-99%	30	26	36
100%	66	70	59

3. Approximately how many patients in total do you see in a typical month?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0-300 Patients	25%	30%	16%
301-400 Patients	29	27	31
401-500 Patients	25	20	34
501+ Patients	21	23	19
Mean	433	425	446
Median	400	400	450

4a. Approximately how many patients with menopausal symptoms do you see in a typical month? TERMINATE IF FEWER THAN 2

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
2-35 Patients	22%	12%	40%
36-65 Patients	27	23	35
66-100 Patients	29	34	19
100+ Patients	22	31	7
Mean	85	104	52
Median	70	80	40

% of patients with menopause symptoms out of all patients that you see

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0%-10%	33%	16%	62%
11%-20%	31	33	27
21%-30%	13	18	6
31%+	23	33	5
Mean	21	26	12

4b. Approximately how many patients in total with menopausal symptoms do you currently see?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
2-150 Patients	23%	18%	34%
151-350 Patients	25	18	36
351-750 Patients	25	27	20
750+ Patients	27	37	10
Mean	626	783	353
Median	400	500	250

5. Approximately how many patients with menopausal symptoms do you initiate on hormone therapy per month?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0 Patients	2%	0%	5%
1-5 Patients	29	19	47
6-15 Patients	23	20	27
16-30 Patients	25	30	18
30+ Patients	21	31	3
Mean	26	34	11
Median	15	20	5

6. For how many years (post-residency or post-fellowship) have you been treating menopausal patients? TERMINATE IF LESS THAN 6 YEARS

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
6-12 Years	20%	18%	24%
13-20 Years	32	31	32
21-25 Years	30	31	29
26+ Years	18	20	15
Mean	20	20	19
Median	20	21	20

6a. Do you consider menopause management to be a focus or specialty within your individual practice?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Yes	64%	100%	0%
No	36	0	100

Many of the questions in this survey ask about hormone therapy for menopausal symptoms, and we use the abbreviation HT to mean hormone therapy. Unless noted otherwise, HT includes *both* estrogen therapy (ET) and estrogen+progestin therapy (EPT).

7. Of all your patients with menopausal symptoms:

- a. Approximately what percentage are currently on HT (includes estrogen-only or estrogen + progestin)?

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
0%	0%	0%	0%
1%-10%	15	11	22
11%-20%	18	15	21
21%-30%	21	21	22
31%-50%	23	25	20
51%-75%	16	21	9
76%-100%	7	7	6
Mean	37	40	32

- b. Approximately what percentage are reluctant to start HT (includes estrogen-only or estrogen + progestin), even after discussion with you?

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
0%	0%	0%	0%
1%-10%	12	14	7
11%-20%	17	19	13
21%-30%	18	22	13
31%-50%	26	20	36
51%-75%	15	15	15
76%-100%	12	10	16
Mean	42	38	48



- c. Approximately what percentage specifically ask you to put them on HT (includes estrogen-only or estrogen + progestin)?

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
0%	3%	3%	4%
1%-10%	46	40	55
11%-20%	24	27	17
21%-30%	13	13	14
31%-50%	11	13	9
51%-75%	2	3	0
76%-100%	1	1	1
Mean	19	21	16

- d. Approximately what percentage specifically ask you NOT to put them on HT (includes estrogen-only or estrogen + progestin)?

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
0%	2%	1%	3%
1%-10%	29	32	25
11%-20%	22	23	18
21%-30%	18	18	19
31%-50%	15	14	17
51%-75%	7	6	10
76%-100%	7	6	8
Mean	29	27	32

e. Approximately what percentage are specifically on estrogen-only therapy (ET)?

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
0%	1%	1%	2%
1%-10%	31	27	38
11%-20%	25	26	24
21%-30%	19	22	15
31%-50%	15	16	11
51%-75%	7	7	6
76%-100%	2	< 1	4
Mean	24	25	23

Summary of mean percentages of all your patients with menopausal symptoms:

% of all patients with menopausal symptoms	ALL (n=404)	MM (n=202)	General (n=202)
(columns exceeds 100%)			
Currently on HT	37%	40%	32%
Reluctant to start HT	42	38	48
Specifically ask to be on HT	19	21	16
Specifically ask NOT to be on HT	29	27	32
On estrogen-ONLY therapy	24	25	23

8. When it comes to treating moderate or severe menopausal symptoms, do you primarily think of HT as:

	ALL (n=404)	MM (n=202)	General (n=202)
A first line treatment	74%	82%	62%
A second line treatment (or third, fourth, etc.) when alternatives and/or lifestyle changes don't work	26	18	38



9. How important to you are each of the following when deciding whether to prescribe HT for your patients?

a. Severity of symptoms

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	0%	0%	0%
Not very important	0	0	0
Somewhat important	19	17	22
Very important	81	83	78

b. Range and specific types of symptoms

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	< 1%	< 1%	< 1%
Not very important	3	2	5
Somewhat important	47	42	54
Very important	50	56	41

c. Patient request

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	< 1%	0%	< 1%
Not very important	6	6	6
Somewhat important	50	45	58
Very important	44	49	36

d. The patient's personal medical history

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	0%	0%	0%
Not very important	2	2	2
Somewhat important	21	23	18
Very important	77	75	80

e. The risks of HT (e.g., increased risk of coronary heart disease, breast cancer, etc.)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	< 1%	< 1%	< 1%
Not very important	6	7	5
Somewhat important	32	36	26
Very important	61	56	68

f. Prevention of osteoporosis and/or concerns with bone mineral density (BMD)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	4%	2%	6%
Not very important	15	10	23
Somewhat important	57	61	51
Very important	24	27	20

g. Age of patient

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all important	2%	2%	1%
Not very important	11	10	14
Somewhat important	54	53	55
Very important	33	35	30

h. Family history (volunteered by n=21)

	ALL	MM	General
	(n=21)	(n=9)	(n=12)
Not at all important	32%	41%	24%
Not very important	4	0	8
Somewhat important	35	33	37
Very important	29	26	32

Cost/formulary (volunteered by n=10)

	ALL	MM	General
	(n=10)	(n=7)	(n=3)
Not at all important	28%	27%	33%
Not very important	28	27	33
Somewhat important	44	46	33
Very important	0	0	0

Summary of percentages of Very Important for each deciding factor:

% Very important	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Severity of symptoms	81%	83%	78%
Range and specific types of symptoms	50	56	41
Patient request	44	49	36
The patient's personal medical history	77	75	80
The risks of HT	61	56	68
Prevention of osteoporosis	24	27	20
Age of patient	33	35	30
Family history (vol., n=21)	29	26	32
Cost/formulary (vol., n=10)	0	0	0

10. How concerned are you generally about the risks *specifically of estrogen+progestin (EPT) therapy* for:

a. Younger menopausal patients (below age 60)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all concerned	7%	9%	3%
Not very concerned	31	34	27
Somewhat concerned	43	42	44
Very concerned	19	15	26

b. Older menopausal patients (age 60 and above)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all concerned	1%	1%	0%
Not very concerned	10	12	8
Somewhat concerned	58	57	58
Very concerned	31	30	34

11. (SKIP IF NOT AT ALL CONCERNED IS SELECTED FOR BOTH 10a AND 10b)
 Which risks concern you about prescribing *estrogen+progestin (EPT) therapy* for menopausal symptoms? (*Fixed choices with Other specify*)

	ALL	MM	General
	(n=400)	(n=198)	(n=202)
<i>(Multiple responses accepted; total exceeds 100%)</i>			
Blood clots	88%	88%	87%
Breast Cancer	87	84	92
Coronary heart disease	74	73	76
Stroke	73	72	74
Dementia	14	15	13
Other (< 1% per mention)	3	3	3

12. What do you see as valuable about EPT for treating menopausal symptoms?
(Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Relieves hot flashes	100%	100%	99%
Relieves vaginal dryness and painful intercourse	92	94	90
Improves menopause-related sleep problems	88	91	83
Prevents bone loss	84	86	80
Reduces depression and mood changes	68	68	69
Reduces the risk of colorectal cancer	37	43	26
Prevents cardiovascular disease	16	18	11
Other (< 1% per mention)	3	4	1
NONE	0	0	0

13. How concerned are you about the risks *specifically of estrogen-only therapy (ET)* for:

a. Younger menopausal patients (below age 60)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all concerned	9%	12%	5%
Not very concerned	32	37	24
Somewhat concerned	40	36	46
Very concerned	19	15	25

b. Older menopausal patients (age 60 and above)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not at all concerned	2%	3%	0%
Not very concerned	23	28	14
Somewhat concerned	52	48	58
Very concerned	23	21	28

14. (SKIP IF NOT AT ALL CONCERNED IS SELECTED FOR BOTH 13a AND 13b)
 Which risks concern you about prescribing estrogen-only therapy (ET) for
 menopausal symptoms? (Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=396)	(n=194)	(n=202)
Blood clots	86%	88%	82%
Breast Cancer	71	65	80
Stroke	68	70	65
Coronary heart disease	51	50	52
Dementia	8	8	9
Uterine Cancer (vol.)	4	5	3
Other (<1% per mention)	3	2	5

15. What do you see as valuable about ET for treating menopausal symptoms?
 (Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Relieves hot flashes	99%	100%	98%
Relieves vaginal dryness and painful intercourse	94	94	93
Improves menopause-related sleep problems	84	86	81
Prevents bone loss	81	82	79
Reduces depression and mood changes	71	72	69
Reduces the risk of colorectal cancer	35	42	22
Prevents cardiovascular disease	19	23	12
Other (< 1% per mention)	3	4	1
NONE	< 1	0	< 1

16. In your view are the risks of HT understated, overstated, or accurately perceived by the following groups:

a. The media

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	3%	2%	4%
Accurately perceived	6	4	9
Overstated	88	92	82
Don't know	3	2	5

b. The patients you see

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	8%	7%	10%
Accurately perceived	15	11	22
Overstated	73	79	62
Don't know	4	3	6

c. Family or general practitioners

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	5%	4%	6%
Accurately perceived	46	37	63
Overstated	40	50	23
Don't know	9	9	8

d. Internists

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	3%	4%	2%
Accurately perceived	47	37	63
Overstated	40	50	24
Don't know	10	9	11

e. Obstetrician/gynecologists

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	13%	8%	20%
Accurately perceived	72	77	65
Overstated	10	11	8
Don't know	5	4	7

f. Endocrinologists

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Understated	4%	4%	3%
Accurately perceived	62	58	69
Overstated	15	21	6
Don't know	19	17	22

Summary of perceived risks of HT:

Means based on the following:

- 1 = Understated
- 2 = Accurately perceived
- 3 = Overstated

	ALL	MM	General
Means for:	(n=404)	(n=202)	(n=202)
The media	2.9	2.9	2.8
The patients you see	2.7	2.7	2.6
Family or general practitioners	2.4	2.5	2.2
Internists	2.4	2.5	2.2
Obstetrician/gynecologists	2.0	2.0	1.9
Endocrinologists	2.1	2.2	2.0

The next set of questions are about findings from the Women's Health Initiative (referred to as the WHI) that were released in 2002 and 2004.

17. How familiar are you with the WHI?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not familiar (have not yet read or learned much about the WHI findings)	4%	2%	6%
Somewhat familiar (aware of the WHI findings about risks and benefits of HT, but would need to consult a reference source for specific information or findings)	42	34	56
Very familiar (know the specific risks and benefits of HT according to the WHI)	37	39	34
Extremely familiar (know a great deal including details about the study design and ongoing interpretation of the scientific data)	17	25	4

18. As of today, how much confusion do you feel there is currently about the WHI findings?

[OFFER CHECK BOX AT BOTTOM OF SCREEN TO SKIP OUT OF ENTIRE GRID – IF CHECKED, SKIP NEXT THREE QUESTIONS] Not familiar enough with WHI findings to answer

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Not familiar enough with WHI findings	1%	1%	2%
Familiar enough	99	99	98

a. For you personally

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
No confusion at all	18%	22%	10%
Not very much confusion	42	41	43
Some confusion	35	32	42
A great deal of confusion	4	4	4
Don't know	1	1	1

b. Within the media

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
No confusion at all	< 1%	0%	< 1%
Not very much confusion	2	2	3
Some confusion	28	24	35
A great deal of confusion	67	73	57
Don't know	3	1	5

c. Among the patients you see

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
No confusion at all	0%	0%	0%
Not very much confusion	3	2	4
Some confusion	27	22	37
A great deal of confusion	68	75	55
Don't know	2	1	4

d. Among family or general practitioners

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
No confusion at all	2%	2%	2%
Not very much confusion	13	8	20
Some confusion	51	47	59
A great deal of confusion	25	35	8
Don't know	9	8	11

e. Among internists

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
No confusion at all	2%	2%	3%
Not very much confusion	18	12	27
Some confusion	46	45	50
A great deal of confusion	24	33	8
Don't know	10	8	12

f. Among obstetrician/gynecologists

	ALL (n=398)	MM (n=201)	General (n=197)
No confusion at all	5%	6%	5%
Not very much confusion	46	41	53
Some confusion	36	41	26
A great deal of confusion	7	7	6
Don't know	6	5	10

g. Among endocrinologists

	ALL (n=398)	MM (n=201)	General (n=197)
No confusion at all	6%	5%	6%
Not very much confusion	36	29	47
Some confusion	34	40	24
A great deal of confusion	6	9	2
Don't know	18	17	21

Summary of confusion about WHI findings:

Means based on the following:

1 = Not confused at all

3 = Some confusion

2 = Not very much confusion

4 = A great deal of confusion

	ALL (n=398)	MM (n=201)	General (n=197)
Means for:			
For you personally	2.3	2.2	2.4
Within the media	3.7	3.7	3.6
Among the patients you see	3.7	3.7	3.5
Among family or general practitioners	3.1	3.3	2.8
Among internists	3.0	3.2	2.7
Among obstetrician/gynecologists	2.5	2.5	2.4
Among endocrinologists	2.5	2.6	2.3

19. How does this compare to when the WHI findings were first released in 2002?

a. For you personally

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	23%	29%	13%
Somewhat less confusion now	36	36	35
The same	26	21	35
Somewhat more confusion now	10	9	13
A lot more confusion now	2	2	0
Don't know	3	3	4

b. Within the media

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	< 1%	< 1%	< 1%
Somewhat less confusion now	11	11	10
The same	46	46	46
Somewhat more confusion now	18	18	18
A lot more confusion now	17	20	13
Don't know	7	4	12

c. Among the patients you see

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	1%	1%	1%
Somewhat less confusion now	11	11	13
The same	46	46	47
Somewhat more confusion now	23	24	21
A lot more confusion now	14	16	10
Don't know	5	2	8

d. Among family or general practitioners

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	2%	2%	2%
Somewhat less confusion now	22	19	26
The same	43	43	42
Somewhat more confusion now	13	15	11
A lot more confusion now	7	9	2
Don't know	13	12	17

e. Among internists

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	3%	3%	4%
Somewhat less confusion now	25	24	28
The same	39	38	39
Somewhat more confusion now	13	15	11
A lot more confusion now	6	8	1
Don't know	14	12	17

f. Among obstetrician/ gynecologists

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	14%	16	11
Somewhat less confusion now	34	38	28
The same	31	28	34
Somewhat more confusion now	9	9	9
A lot more confusion now	2	2	2
Don't know	10	7	16

g. Among endocrinologists

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
A lot less confusion now	10%	11%	7%
Somewhat less confusion now	31	33	29
The same	26	24	29
Somewhat more confusion now	8	9	6
A lot more confusion now	2	3	2
Don't know	23	20	27

Summary of confusion compared to when the WHI findings were first released
 In 2002:

Means based on the following:

- 1 = A lot less confusion now
- 2 = Somewhat less confusion now
- 3 = The same
- 4 = Somewhat more confusion now
- 5 = A lot more confusion now

	ALL	MM	General
Means for	(n=398)	(n=201)	(n=197)
For you personally	2.3	2.2	2.5
Within the media	3.4	3.5	3.4
Among the patients you see	3.4	3.5	3.3
Among family or general practitioners	3.0	3.1	2.8
Among internists	2.9	3.0	2.7
Among obstetrician/gynecologists	2.4	2.4	2.6
Among endocrinologists	2.5	2.5	2.5

20. There has been much discussion about the WHI methodology and findings. Which aspects of the WHI, if any, do you feel influence its applicability to your practice? *(Fixed choices with Other specify)*

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=398)	(n=201)	(n=197)
Included only post-menopausal, not early-menopausal women	73%	80%	60%
Only one dosage strength was studied	58	65	46
Non-oral HT delivery mechanisms were not studied (including injectable, patch, vaginal delivery or gel/cream/emulsion)	61	65	53
Women with severe menopausal symptoms were excluded	48	55	37
Only one drug was studied in each study arm	48	55	36
Other (< 1% per mention)	5	6	3
None	11	6	19

21. How much have the WHI findings affected your practice in the following areas?

a. How many patients you recommend HT for

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
Not at all	6%	7%	4%
Not very much	15	16	14
Somewhat	46	48	41
Very much	33	29	41

b. How long you advise patients to take HT

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
Not at all	3%	4%	2%
Not very much	8	9	6
Somewhat	38	41	32
Very much	51	46	60

c. How much you need to counsel patients about the risks and benefits of HT

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
Not at all	1%	2%	1%
Not very much	5	5	4
Somewhat	24	23	27
Very much	70	70	68

d. How much concern patients are expressing about HT

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
Not at all	1%	1%	1%
Not very much	4	2	6
Somewhat	29	27	34
Very much	66	70	59

e. The level of misinformation that patients bring to your office

	ALL	MM	General
	(n=398)	(n=201)	(n=197)
Not at all	1%	1%	1%
Not very much	6	3	12
Somewhat	34	27	46
Very much	59	69	41

Summary of percentages of Very Much for each affected area by WHI findings:

% Very much	ALL	MM	General
(Columns exceeds 100%)	(n=398)	(n=201)	(n=197)
How many patients you recommend HT	33%	29%	41%
How long you advise patients to take HT	51	46	60
How much you need to counsel patients about the risks and benefits of HT	70	70	68
How much concern patients express	66	70	59
The level of misinformation that patients bring to your office	59	69	41

The next four questions are about EPT specifically.

22. As a result of the findings released from the WHI in 2002, are you currently prescribing EPT:

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
A lot less	38%	31%	50%
Somewhat less	39	42	34
About the same	20	23	15
Somewhat more	2	3	1
A lot more	1	1	0

23. Please estimate the *percentage* of patients for whom you initially stopped EPT in the three months following the release of the 2002 WHI findings.

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0%	5%	7%	3%
1%-25%	38	39	35
26%-50%	32	32	34
51%-75%	14	13	14
76%-100%	11	9	14
Mean	39	36	42

24. Of all the patients you initially stopped EPT in the three months following the release of the 2002 WHI findings, what percentage have subsequently resumed EPT?

	ALL	MM	General
	(n=378)	(n=184)	(n=194)
0%	8%	6%	12%
1%-25%	55	49	65
26%-50%	26	30	18
51%-75%	7	9	3
76%-100%	4	6	2
Mean	26	31	19

25. (IF MORE THAN 0) Why did you resume prescribing EPT for these patients?
 (Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=345)	(n=174)	(n=171)
Superior symptom relief	78%	81%	72%
Patient request	83	81	85
Alternative therapies have not been successful	73	80	62
The hype has died down and risks have been more reasonably assessed	39	48	24
I have a better understanding of how to make case-by-case judgments	32	35	26
Other (< 1% per mention)	< 1	< 1	0

The next four questions are about ET specifically.

26. As a result of the findings released from the WHI in 2004, are you currently prescribing ET:

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
A lot less	23%	17%	32%
Somewhat less	29	30	28
About the same	35	37	32
Somewhat more	10	12	7
A lot more	3	4	< 1

27. Please estimate the *percentage* of patients for whom you initially stopped ET in the three months following the release of the 2004 WHI findings.

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0%	14%	15%	12%
1%-25%	45	47	43
26%-50%	24	24	24
51%-75%	8	8	7
76%-100%	9	6	14
Mean	29	27	33

28. Of all the patients you initially stopped ET in the three months following the release of the 2004 WHI findings, what percentage have subsequently resumed ET?

	ALL	MM	General
	(n=343)	(n=164)	(n=179)
0%	7%	6%	9%
1%-25%	53	46	64
26%-50%	27	31	21
51%-75%	5	6	4
76%-100%	8	11	2
Mean	29	34	21



29. (IF MORE THAN 0) Why did you resume prescribing ET for these patients?
(Fixed choices with Other specify)

	ALL	MM	General
(Multiple responses accepted; total exceeds 100%)	(n=316)	(n=153)	(n=163)
Superior symptom relief	84%	88%	75%
Patient request	81	81	81
Alternative therapies have not been successful	75	80	67
The hype has died down and risks have been more reasonably assessed	41	53	21
I have a better understanding of how to make case-by-case judgments	33	38	26
Other (< 1% per mention)	1	1	0

30. About how many of your current menopausal patients were referred to you by other physicians who are *less experienced* with menopause management?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0 patients	40%	26%	65%
1-10 patients	23	26	19
11-20 patients	13	17	5
21-50 patients	15	19	8
50+ patients	9	12	3
Mean	23	31	9
Median	5	10	0
% of patients referred by <i>less experienced</i>	4%	4%	3%

31. About how many of your current menopausal patients do you refer to other physicians who are *more experienced* with menopause management?

	ALL (n=404)	MM (n=202)	General (n=202)
0 patients	63%	70%	49%
1-5 patients	14	13	15
6-10 patients	9	8	12
11-50 patients	11	7	19
50+ patients	3	2	5
Mean	8	5	14
Median	0	0	1
% of patients referred to <i>more experienced</i>	1%	< 1%	4%

32. Compared to before the WHI findings were released in 2002, are you referring patients to physicians who are more experienced with menopause management:

	ALL (n=227)	MM (n=84)	General (n=143)
A lot less often	5%	4%	6%
Somewhat less often	5	6	3
About the same as before	70	72	68
Somewhat more often	15	13	18
A lot more often	5	5	5

33. Has it ever happened to you that another doctor has changed your HT prescription or recommendations for a patient?

	ALL (n=404)	MM (n=202)	General (n=202)
Yes	62%	65%	57%
No	19	21	17
Don't know	19	14	26



34. Please estimate the *number* of patients for which this has happened

	ALL	MM	General
	(n=250)	(n=133)	(n=17)
1-5 patients	24%	20%	31%
6-10 patients	25	24	26
11-20 patients	22	22	22
20+ patients	29	34	21
Mean	25	27	23
Median	12	15	10

35. When referred to another physician, which of the following happens *most often*?

	ALL	MM	General
Other physician ...	(n=250)	(n=133)	(n=17)
... takes patient off HT	40%	49%	23%
... puts patient on HT	13	6	28
... decreases dosage of HT	5	4	7
... increases dosage of HT	3	4	2
... shortens time span for therapy	5	6	4
... lengthens time span for therapy	2	3	1
... changes form of HT administration	16	12	21
Don't know	16	16	14



36. When physicians disagree about HT for the same patient, why do you think they most often disagree? *(Fixed choices with Other specify)*

	ALL (n=250)	MM (n=133)	General (n=17)
Different specialties means they focus on different patient issues	36%	35%	37%
Different opinions about how to interpret and apply the WHI findings	36	36	36
Different depth of experience with HT on which to base decisions	22	23	18
Professional Society Treatment Guidelines vary by specialty	2	2	3
Some have more recent information about HT	1	0	4
Food and Drug Administration HT guidelines are unclear	1	2	0
Other (< 1% per mention)	2	2	2

37. What do you think would be useful to generate consensus about menopause management among physicians: *(Fixed choices with Other specify)*

	ALL (n=250)	MM (n=133)	General (n=17)
<i>(Multiple responses accepted; total exceeds 100%)</i>			
Standardized clinical guidelines across specialties	75%	73%	81%
Better data/more studies about HT	54	55	53
More CME about WHI	37	40	31
Peer-reviewed journal articles	25	26	25
Other (< 1% per mention)	5	5	4



38. When two physicians disagree about HT for their patient, what action should the patient take? *(Fixed choices with Other specify)*

	ALL (n=250)	MM (n=133)	General (n=17)
Take careful documentation from each physician, and share it	26%	26%	26%
Ask the physician changing the recommendation to take the lead in initiating a conversation with the initial physician	32	29	39
Carefully select physicians who can work together on this issue	23	26	17
Obtain a third opinion from a menopausal expert	11	12	10
Let the patient decide (vol.)	3	2	4
Something else (< 1% per mention)	5	5	4

39. When you and another physician disagree about HT for a particular patient, which of the following would you prefer to have happen? *(Fixed choices with Other specify)*

	ALL (n=250)	MM (n=133)	General (n=17)
Patient communicates information between both physicians	9%	8%	11%
The physician changing the recommendation takes the lead in initiating a conversation with me	53	54	51
Patient makes her own best decision	18	15	23
Patient follows the advice of the physician with more HT experience	15	18	11
Patient obtains a third opinion	3	3	3
Something else (< 1% per mention)	2	2	1

40. Which risks of HT, if any, do your patients express the *most* concern about?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Breast cancer	81%	83%	79%
Coronary heart disease	8	7	10
Stroke	5	4	6
Blood clots	5	5	4
Endometrial cancer	1	1	1
Dementia	0	0	0
Other	0	0	0
My patients do not typically express concern	< 1	0	< 1

41. How often do you discuss with your patients:

a. The risk/benefit trade-offs of HT, including lifestyle and family history factors

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	0%	0%	0%
Not very often	1	1	1
Occasionally	8	7	11
Very often	49	46	53
All the time	42	46	35

b. The specific findings of the WHI

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	1%	< 1%	1%
Not very often	10	6	17
Occasionally	28	25	31
Very often	39	39	40
All the time	22	29	11

c. Lifestyle changes they can make to relieve menopausal symptoms

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	1%	1%	< 1%
Not very often	6	6	6
Occasionally	25	22	30
Very often	43	42	46
All the time	25	29	17

d. Non-hormonal treatment options for menopausal symptoms

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	0%	0%	0%
Not very often	9	11	7
Occasionally	20	16	25
Very often	46	44	50
All the time	25	29	18

e. Different delivery methods of HT available (pills, patches, creams, etc.)

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	0%	0%	0%
Not very often	7	5	12
Occasionally	24	18	34
Very often	38	38	38
All the time	31	39	16

f. How long they should be on HT

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	0%	0%	0%
Not very often	3	3	3
Occasionally	12	9	18
Very often	48	45	53
All the time	37	43	26

Summary of discussing with patients All the time:

% All the time	ALL	MM	General
	(n=404)	(n=202)	(n=202)
The risk/benefits trade-off of HT	42%	46%	35%
The specific findings of WHI	22	29	11
Lifestyle changes to relieve symptoms	25	29	17
Non-hormonal treatment options	25	29	18
Diff. delivery methods of HT available	31	39	16
How long they should be on HT	37	43	26

42. How often do you feel that you have enough time to answer your patients' questions and concerns about the risks and benefits of HT and the treatment options they can choose from?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Never	< 1%	< 1%	1%
Not very often	18	12	29
Occasionally	28	27	29
Very often	41	46	33
All the time	12	14	8

43. Compared to before the WHI findings were released in 2002, how much time do you find yourself spending answering patient questions and concerns about the risks and benefits of HT?

	ALL (n=404)	MM (n=202)	General (n=202)
Less time	4%	3%	6%
The same time	13	10	18
A little more time	37	35	39
A lot more time	46	52	37

44. (IF MORE TIME) Why do you feel the discussion now takes more time?
 (Fixed choices with Other reasons specify)

	ALL (n=321)	MM (n=170)	General (n=151)
<i>(Multiple responses accepted; total exceeds 100%)</i>			
The information about risks and benefits is complex	82%	81%	84%
The level of misinformation that patients bring to your office	72	78	60
Lack of consensus	53	55	49
More HT treatment options are available for patients to choose from	38	46	23
Other reasons (< 1% per mention)	1	1	1

45. (IF LESS TIME) Why do you feel the discussion now takes less time?

	ALL (n=21)	MM (n=8)	General (n=13)
<i>(Open-ended answers)</i>			
Patients do not want HT or care about HT	42%	51%	34%
Not using HT	12	2	21
No other alternatives	12	25	0
Decision made/preformed ideas	9	0	17
Easier to explain with evidence/information	7	5	8
More patients/less time available	6	0	12
Other (one mention each, by n=3)	24	42	8



ALTERNATIVE DELIVERY FOR HT

For the next set of questions, please think about estrogen-only therapy (abbreviated as ET).

46. For approximately how many of your current ET patients have you prescribed non-oral delivery mechanisms (including injectable, patch, vaginal delivery or gel/cream/emulsion)?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
0	3%	1%	6%
1-10	22	18	29
11-30	29	26	35
31-50	22	24	17
51-100	16	19	9
101+	9	12	4
Mean	60	73	37
Median	30	40	20
% of ET patients prescribed non-oral	39%	37%	46%

47. When you prescribe non-oral ET, what is your reason most often? *(Fixed choices with Other reasons specify)*

	ALL (n=384)	MM (n=197)	General (n=187)
No first-pass metabolism	34%	39%	25%
Specific patient request	23	20	28
Convenience	15	14	16
Non-orals provide less estrogen per dose	10	8	13
Patients don't have to remember a pill every day	6%	7%	5%
Patients express concern about how many pills they already take	3	3	3
Availability of samples	2	3	< 1
Non-orals were not studied in the WHI	1	1	3
To treat vaginal symptoms (vol.)	1	1	2
Formulary coverage	< 1	0	1
Non-orals are discrete	< 1	0	< 1
Other (< 1% per mention)	4	4	4

48. When given a choice, what is the reason most often that some patients select non-oral ET? *(Fixed choices with Other specify)*

	ALL (n=384)	MM (n=197)	General (n=187)
Patients don't have to remember a pill every day	42%	44%	39%
One less pill for the patient to take	16	15	19
No bad press around non-orals	13	12	17
One less thing that has to be metabolized by the liver	11	11	10
Non-orals were not studied in the WHI	2	2	2
Covered by insurance	2	2	2
Availability of samples	2	2	< 1
Better symptom control (vol.)	2	2	1
Doctor recommendation (vol.)	2	2	<1
Non-orals are discrete	1	1	1
Other (< 1% per mention)	8	8	9

49. When given a choice, what is the reason most often that some patients do *not* select non-oral ET? (Fixed choices with Other specify)

	ALL	MM	General
	(n=384)	(n=197)	(n=187)
More familiar with pills	42%	44%	39%
Skin sensitivities	23	26	18
Convenience	13	11	18
Not covered by insurance	12	10	14
Non-orals are messy	7	6	9
Non-orals are less discrete	1	1	0
Availability of samples	< 1	1	0
Other (< 1% per mention)	1	< 1	2

50. Please think about the patients for whom you prescribe ET. In the last two years, how has your prescribing of non-oral delivery mechanisms for these patients changed? I'm prescribing non-oral therapies...

	ALL	MM	General
	(n=384)	(n=197)	(n=187)
A lot less often	2%	2%	3%
Somewhat less often	5	4	8
About the same	50	46	57
Somewhat more often	36	39	29
A lot more often	7	9	3

51. Which non-oral ET do your patients prefer most often?

	ALL	MM	General
	(n=384)	(n=197)	(n=187)
Transdermal patch	71%	73%	68%
Injectable	2	2	< 1
Gel, cream, or emulsion	23	20	28
Vaginal ring	4	5	3

SOURCES OF INFORMATION

52. Where do you get your information about the risks and benefits of HT?
(Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Medical Journals	90%	91%	89%
CME programs	69	73	61
Medical meetings	61	67	50
Drug company sales representatives	44	47	40
Other Physicians	31	29	35
Internet	23	23	23
The media	9	9	9
Other (< 1% per mention)	1	1	1

53. Where are your patients getting information about the risks and benefits of HT?
(Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Their friends and family	82%	86%	74%
News media reports	82	84	80
Internet	80	79	81
From me (their physician)	77	79	74
From other health care professionals	43	47	36
From a pharmacist	41	45	35
Drug company advertising	40	42	37
Non-medical wellness instructors (yoga, personal trainers, etc.)	33	35	30
Patient education organizations/support groups (NAMS, Hormone Foundation, ACOG, ASRM, etc.)	19	20	19
Other (< 1% per mention)	1	1	< 1



54. Where do you get the information *that you give to patients* about the risks and benefits of HT? (Fixed choices with Other specify)

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=398)	(n=200)	(n=198)
Medical journal articles	74%	75%	72%
Drug company materials (print/websites)	52	55	46
Patient education organizations/support groups (NAMS, Hormone Foundation, ACOG, ASRM, etc.)	44	52	32
Other physicians	20	20	21
Media articles	10	9	12
Other	0	0	0

55. Do you feel that you need *more* information about menopause and HT to give to your patients?

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Yes	58%	60%	56%
No	42	40	44

OPPORTUNITIES FOR IMPROVEMENT

56. What kinds of educational tools do you think are valuable for your menopausal patients? *(Fixed choices with Other specify)*

<i>(Select up to three)</i>	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
A fact sheet or brochure	83%	83%	84%
More balanced media coverage	52	54	47
More website content	29	28	31
Public service announcements and awareness campaigns	28	30	25
A toll-free 1-800 number to call for information about HT	20	20	20
A DVD or video	18	20	15
A downloadable educational program	17	16	17
Materials in languages other than English	8	10	6
Other (< 1% per mention)	< 1	< 1	0

57. What kinds of patient tools would be valuable for you to help your patients when it comes to menopause management? *(Fixed choices with Other specify)*

<i>(Select up to three)</i>	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Take-away fact sheet or brochure	92%	92%	92%
A downloadable website content	34	35	3
A DVD or video for your practice	28	31	24
Posters, displays and wall charts for your practice	21	18	27
Materials in languages other than English	14	16	11
Other (< 1% per mention)	2	2	2



58. Thinking about the tools you just selected as being potentially valuable, which topics would be valuable to address via these tools? *(Fixed choices with Something Else specify)*

<i>(Select up to three)</i>	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
The risks and benefits of HT	96%	96%	95%
WHI findings and what they mean	69	68	71
Alternative HT delivery methods and how to take them	54	56	50
Alternatives to HT	49	45	55
Something else (< 1% per mention)	1	1	0

59. Thinking again about the things that menopausal women can do to help you work with them to manage their menopausal symptoms better, which of the following would be valuable: *(Fixed choices with Something Else specify)*

<i>(Select up to three)</i>	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Documenting and prioritizing their symptoms, how often, how severe, etc.	64%	64%	63%
Thinking through their own risk/benefit comfort level prior to a consultation	62	61	64
Coming in with a list of questions prepared	50	56	40
Learning about HT in general ahead of time	44	43	47
Documenting their family history for me	35	36	34
Involving a spouse or other family member in the decision	8	9	7
Something else (< 1% per mention)	< 1	1	0
None of these	1	0	2



60. What kinds of information and education would be valuable *for you* to help you provide the best care for your menopausal patients? *(Fixed choices with Other specify)*

	ALL	MM	General
<i>(Multiple responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Information about menopause management	87%	88%	86%
Information about the WHI	64	61	71
Information for allied health professionals and nurses who work with menopausal women	30	34	24
Other (< 1% per mention)	1	1	1

61 a. What will be your biggest challenge in treating menopausal women over the next five years?

	ALL	MM	General
<i>(Multiple open-end responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Combating misinformation/misconceptions/media	23%	26%	19%
Addressing patient concerns about HT risks	14	18	7
NET Treatment guidelines, including:	12	11	12
Deciding length of treatments	5	5	5
Knowing patient type for benefit	3	3	4
Customizing treatments	2	3	1
Vague guidelines on HT	1	1	1
Maximum age for HT	1	1	< 1
Dosing	1	1	< 1
Educating patients	11	12	11
Keeping up with new/changing /conflicting information	10	11	9
Finding alternative treatments	9	8	12
Weighing risks vs. benefits of treatment	9	8	11
Lack of sufficient evidence/accurate information	5	5	6
Risk from HT (safety)	5	4	6
Insurance coverage/reimbursement	3	3	2
Compliance/patients' commitment	3	3	2
Lack of time to educate patients	2	3	2
Legal liabilities	2	1	3
Increasing number of patients	2	2	1
Other (< 2% per mention)	10	10	9
Don't know	2	1	4
None	1	< 1	1



61b. How can The Hormone Foundation/Endocrine Society help you with that challenge? *(Fixed choices with Other specify)*

	ALL	MM	General
<i>(Multiple open-end responses accepted; total exceeds 100%)</i>	(n=404)	(n=202)	(n=202)
Provide more patient education material (brochure, online, etc.)	31%	30%	33%
Clear consensus on risks and benefits/guidelines/recommendations for physicians	19	20	17
Educate the public	14	16	12
Provide nonbiased, accurate information	12	14	8
Educate the media	10	12	7
Fund/support research studies	9	8	11
Review of new research and up-to-date information	8	7	9
Clear up WHI results/findings	5	6	3
Providing information on alternative therapy	3	4	1
CME	3	2	4
Hold conferences/symposiums to develop consensus	2	2	2
Lobby for Medicare and insurance company to cover medications	2	2	1
Other (< 2% per mention)	7	8	7
Don't Know/No answer	8	7	10

DEMOGRAPHICS

62. Are you:

	ALL	MM	General
	(n=401)	(n=201)	(n=200)
Male	80%	75%	88%
Female	20	25	12

63. In what year were you born?

Age	ALL	MM	General
	(n=379)	(n=189)	(n=190)
45 or below	18%	16%	22%
46-50	23	22	25
51-55	28	29	27
56-60	16	16	15
61+	14	17	11
Mean	52.0	52.7	50.9

64. What section of the country do you currently practice in?

	ALL	MM	General
	(n=404)	(n=202)	(n=202)
Midwest	25%	27%	22%
Northeast	28	25	32
South	32	35	28
West	15	14	18